The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
出版年份 2013 全文链接
标题
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
作者
关键词
-
出版物
SCIENCE
Volume 343, Issue 6168, Pages 305-309
出版商
American Association for the Advancement of Science (AAAS)
发表日期
2013-11-30
DOI
10.1126/science.1244917
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Genome-wide identification of Ikaros targets elucidates its contribution to mouse B-cell lineage specification and pre-B-cell differentiation
- (2013) I. Ferreiros-Vidal et al. BLOOD
- High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone
- (2013) Daniel Heintel et al. BRITISH JOURNAL OF HAEMATOLOGY
- Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
- (2013) Jakob Lovén et al. CELL
- RNA-Guided Human Genome Engineering via Cas9
- (2013) P. Mali et al. SCIENCE
- Multiplex Genome Engineering Using CRISPR/Cas Systems
- (2013) L. Cong et al. SCIENCE
- High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance
- (2012) A. Broyl et al. BLOOD
- BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia
- (2012) C. J. Ott et al. BLOOD
- Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression
- (2012) Ling-Hua Zhang et al. BRITISH JOURNAL OF HAEMATOLOGY
- Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
- (2012) Yibin Yang et al. CANCER CELL
- Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
- (2012) A Lopez-Girona et al. LEUKEMIA
- Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma
- (2012) Yuan Xiao Zhu et al. LEUKEMIA & LYMPHOMA
- Negative regulators take center stage
- (2012) Silvia Monticelli et al. NATURE IMMUNOLOGY
- Aiolos promotes TH17 differentiation by directly silencing Il2 expression
- (2012) Francisco J Quintana et al. NATURE IMMUNOLOGY
- Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
- (2011) Y. X. Zhu et al. BLOOD
- Single-vector inducible lentiviral RNAi system for oncology target validation
- (2011) Dmitri Wiederschain et al. CELL CYCLE
- Multiple Myeloma
- (2010) Jacob Laubach et al. Annual Review of Medicine
- Ikaros in immune receptor signaling, lymphocyte differentiation, and function
- (2010) Matthias Merkenschlager FEBS LETTERS
- Identification of a Primary Target of Thalidomide Teratogenicity
- (2010) T. Ito et al. SCIENCE
- Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
- (2009) Paul G. Richardson et al. JOURNAL OF CLINICAL ONCOLOGY
- An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
- (2009) Teresa A. Soucy et al. NATURE
- Mutation ofFOXL2in Granulosa-Cell Tumors of the Ovary
- (2009) Sohrab P. Shah et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global Protein Stability Profiling in Mammalian Cells
- (2008) H.-C. S. Yen et al. SCIENCE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started